1 March 2008 in The Lancet
WFW Wolfgang Fleischhacker
+13
1 June 2009 in American Journal of Psychiatry
WFWolfgang W. Fleischhacker
Wolfgang W. Fleischhacker
+14
1 March 2013 in European Neuropsychopharmacology
FGfor the EUFEST Study Group
for the EUFEST Study Group
+2
1 December 2009 in Schizophrenia Research
1 December 2009 in Schizophrenia Research
WFW Wolfgang Fleischhacker
+2
1 November 2002 in European Psychiatry
Summary: The first choice group of psychotropic agents in schizophrenia is neuroleptics. However, this treatment is not effective in all patients and with every symptom. We summarize papers published on the role of antiepileptic drugs in treatment-resistant schizophrenia. We have searched the computer database system MEDLINE for relevant articles including reviews, reports of drug studies and case histories. Antiepileptic drugs can change symptoms of schizophrenia by their action on GABA-ergic neurotransmission or via anti-glutamatergic mechanisms. High doses of adjunctive benzodiazepines reduce positive symptoms, anxiety, and agitation. Carbamazepine is effective in affective symptoms of schizophrenia and influences violent behavior in psychotic patients. Its anti-kindling action may represent a promising treatment strategy for some patients with chronic course of schizophrenia. Valproate treatment leads to a decrease in positive symptoms as well as hostility. Lamotrigine is expected to influence the positive, negative, affective, and cognitive symptoms of schizophrenia. New antiepileptics (e.g., gabapentin, oxcarbazepine, topiramate, vigabatrin) present a promise as potential adjuncts to neuroleptic treatment in resistant symptoms of schizophrenia.